MX2015005675A - Composiciones y metodos para modular la comunicacion celular. - Google Patents

Composiciones y metodos para modular la comunicacion celular.

Info

Publication number
MX2015005675A
MX2015005675A MX2015005675A MX2015005675A MX2015005675A MX 2015005675 A MX2015005675 A MX 2015005675A MX 2015005675 A MX2015005675 A MX 2015005675A MX 2015005675 A MX2015005675 A MX 2015005675A MX 2015005675 A MX2015005675 A MX 2015005675A
Authority
MX
Mexico
Prior art keywords
compositions
cell signaling
methods
modulating cell
gdas
Prior art date
Application number
MX2015005675A
Other languages
English (en)
Inventor
Timothy Alan Springer
Leonard Ira Zon
Nagesh K Mahanthappa
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MX2015005675A publication Critical patent/MX2015005675A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención suministra agentes dirigidos de factor de crecimiento (GDA), los cuales actúan bien sea como antagonistas o agonistas de señalización celular, particularmente en el TGE-beta y las trayectorias de señalización de matriz extracelular relacionadas. Dichos GDA incluyen anticuerpos monoclonales, proteínas de fusión y composiciones de polipéptido novedosas y/o conjugados de estas composiciones.
MX2015005675A 2012-11-06 2013-11-06 Composiciones y metodos para modular la comunicacion celular. MX2015005675A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722919P 2012-11-06 2012-11-06
US201261722969P 2012-11-06 2012-11-06
PCT/US2013/068613 WO2014074532A2 (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling

Publications (1)

Publication Number Publication Date
MX2015005675A true MX2015005675A (es) 2016-02-03

Family

ID=50685303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005675A MX2015005675A (es) 2012-11-06 2013-11-06 Composiciones y metodos para modular la comunicacion celular.

Country Status (10)

Country Link
US (2) US20150284455A1 (es)
EP (1) EP2916867A4 (es)
JP (3) JP2016500704A (es)
AU (3) AU2013341353B2 (es)
CA (2) CA3023553A1 (es)
IL (1) IL238488B (es)
MX (1) MX2015005675A (es)
SG (2) SG11201503271XA (es)
WO (1) WO2014074532A2 (es)
ZA (1) ZA201502884B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
KR20220162801A (ko) 2008-04-11 2022-12-08 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
BR112015001955A2 (pt) 2012-08-24 2017-11-07 Chugai Pharmaceutical Co Ltd variante de região fc específica de fcgamariib
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
EP3816625A1 (en) 2013-05-06 2021-05-05 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
CA2967595A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20180054923A (ko) * 2014-12-19 2018-05-24 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
AU2016206682B2 (en) 2015-01-14 2021-11-11 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-LAP monoclonal antibodies
MX2017008978A (es) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
WO2017015622A2 (en) * 2015-07-22 2017-01-26 Scholar Rock, Inc Gdf11 binding proteins and uses thereof
IL305148A (en) * 2015-09-15 2023-10-01 Scholar Rock Inc Anti-pro/hidden myostatin antibodies and their uses
MY194586A (en) * 2015-09-24 2022-12-05 Daiichi Sankyo Co Ltd Anti-garp antibody
MX2018005061A (es) 2015-11-12 2019-02-28 Siamab Therapeutics Inc Compuestos de interacción con glicanos y métodos de uso.
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用方法
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
KR20180122397A (ko) 2016-03-11 2018-11-12 스칼러 락, 인크. TGFβ1-결합 이뮤노글로불린 및 그의 용도
CA3018221C (en) * 2016-03-31 2023-03-21 Asieris Pharmaceutical Technologies Co., Ltd. Combinational uses of nitroxoline and its analogues with chemotherapies and immunotherapies in the treatment of cancers
HUE051480T2 (hu) 2016-06-13 2021-03-01 Scholar Rock Inc Miosztatin-inhibitorok alkalmazása és kombinációs terápiák
EP3484448A4 (en) 2016-07-13 2020-04-01 President and Fellows of Harvard College MIMETIC SCAFFOLDS OF CELLS HAVING ANTIGEN AND METHODS OF PREPARING AND USING THEM
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
JP2019531070A (ja) * 2016-09-15 2019-10-31 アクセレロン ファーマ インコーポレーテッド ツイスティッド・ガストルレーション・ポリペプチドおよびその用途
AU2018205270B2 (en) 2017-01-06 2022-08-11 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
EP3612625A4 (en) 2017-04-21 2021-08-18 Mellitus, LLC PROCEDURE AND ANTIBODIES FOR DIABETES ASSOCIATED APPLICATIONS
HUE063120T2 (hu) 2017-05-09 2023-12-28 Scholar Rock Inc LRRC33-inhibitorok és alkalmazásuk
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
US11576946B2 (en) 2018-01-29 2023-02-14 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-NFAT interaction
HUE056501T2 (hu) 2018-07-11 2022-02-28 Scholar Rock Inc Izoforma-szelektív TGF-béta1 inhibitorok és alkalmazásuk
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
WO2020160291A2 (en) 2019-01-30 2020-08-06 Scholar Rock, Inc. LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2021030303A1 (en) 2019-08-12 2021-02-18 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
PE20221447A1 (es) 2019-08-28 2022-09-21 Chugai Pharmaceutical Co Ltd Anticuerpos anti-tgf-beta 1 latente y metodos de uso
CN111474336B (zh) * 2020-03-21 2023-07-28 南昌大学 一种铁氰化镍纳米粒化学发光适体传感器的制备方法及基于其检测8-OhdG的方法
WO2022099093A1 (en) * 2020-11-06 2022-05-12 President And Fellows Of Harvard College Scaffolds for enhancing neutrophils and uses thereof
AU2021400488A1 (en) 2020-12-14 2023-06-22 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
CN113061575B (zh) * 2021-03-25 2023-04-07 中国人民解放军陆军军医大学 从大龄小鼠结肠固有层中分离纯化固有淋巴样细胞的方法
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
CN115286701A (zh) * 2022-03-07 2022-11-04 江苏靶标生物医药研究所有限公司 一种调节哺乳动物的肠道粘膜稳态或炎症性肠病的靶点及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
JP3452946B2 (ja) * 1992-02-19 2003-10-06 協和醗酵工業株式会社 抗ＴＧＦ−βマスキングプロテインモノクローナル抗体
WO1994009812A1 (en) * 1992-10-26 1994-05-11 Kirin Brewery Company, Limited METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE
WO1995026203A1 (en) * 1994-03-29 1995-10-05 The Victoria University Of Manchester Wound healing
US5616561A (en) * 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO2005013915A2 (en) * 2003-08-08 2005-02-17 The Regents Of The University Of California Novel indications for transforming growth factor-beta regulators
WO2006106599A1 (ja) * 2005-03-01 2006-10-12 Kyoto University 細胞外ドメインシェディングの異常亢進に起因する疾患の予防及び／又は治療のための医薬
JP5602365B2 (ja) * 2005-10-25 2014-10-08 ザ・ジョンズ・ホプキンス・ユニバーシティ マルファン症候群及び関連疾患を治療するための方法及び組成物。
CA2718495C (en) * 2008-03-14 2022-06-14 Humanzyme Limited Recombinant production of authentic human proteins using human cell expression systems
GB0809592D0 (en) * 2008-05-27 2008-07-02 Imp Innovations Ltd Biomaterials

Also Published As

Publication number Publication date
JP2019163317A (ja) 2019-09-26
JP2017132796A (ja) 2017-08-03
AU2013341353B2 (en) 2017-03-16
IL238488B (en) 2020-04-30
JP2016500704A (ja) 2016-01-14
AU2017203805B2 (en) 2019-08-15
AU2019264599A1 (en) 2019-12-05
EP2916867A4 (en) 2016-10-05
WO2014074532A2 (en) 2014-05-15
WO2014074532A3 (en) 2014-06-26
US20200024339A1 (en) 2020-01-23
SG10201704616SA (en) 2017-07-28
US20150284455A1 (en) 2015-10-08
AU2017203805A1 (en) 2017-06-22
ZA201502884B (en) 2016-01-27
SG11201503271XA (en) 2015-05-28
CA3023553A1 (en) 2014-05-15
EP2916867A2 (en) 2015-09-16
IL238488A0 (en) 2015-06-30
CA2890733A1 (en) 2014-05-15
AU2013341353A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
MX2015005675A (es) Composiciones y metodos para modular la comunicacion celular.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX2021006400A (es) Celulas t de memoria central para terapia adoptiva de celulas t.
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
EA201890423A1 (ru) Слитые белки фактора ix, способы их получения и применения
AU2013211824A8 (en) Fusion proteins comprising IgG2 hinge domains
MX2014014951A (es) Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
MX2017006866A (es) Pares de unión para producción de péptidos.
MX2016012713A (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
WO2013115926A3 (en) Aspartyl-trna synthetase-fc conjugates
MX347515B (es) Agentes que se unen al receptor encrespado y usos de los mismos.
BR112014019901A2 (pt) proteínas de fator viii recombinante
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
PH12014501970A1 (en) Antibodies to bradykinin b1 receptor ligands
EA201491107A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
MX366622B (es) Composicion farmaceutica estable de la proteina de fusion tnfr:fc.
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
NZ703546A (en) Composition comprising a mixture of cd95-fc isoforms
NZ713602A (en) Method for refining protein including self-cutting cassette and use thereof
EA201691532A1 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
MX2015014568A (es) Composiciones y metodos para tratar y prevenir la degeneracion macular.